Princeton, NJ (PRWEB) October 07, 2015
Heart Test Labs mission is to provide accurate, affordable screening tools for the early detection of heart disease, and the MyoVista is the culmination of over 15 years of R&D and $15MM invested to date. OfferBoard Securities, a national investment bank and broker-dealer, will assist Heart Test Labs with raising $2 million in order to fund inventory, working capital and support selling the MyoVista by early 2016.
“Heart disease is common and deadly but treatable if detected early. Unfortunately we still live in a world where most people find out about their condition through a heart attack or worse death” said Heart Test Labs Chairman Andrew Simpson. “While cardiologists have the tools for effective treatment of heart disease,” continued Simpson, “the big diagnostic gap is identifying at an early stage who should seek treatment. This is where the MyoVista comes into play.”
Cardiovascular disease is the leading cause of deaths worldwide accounting for 17.3 million deaths/yr more then all cancers combined; and the largest expenditure in healthcare exceeding $320 billion/yr according to the American Heart Association 2015 Heart Disease and Stroke Statistics Update. Heart Test Labs developed the MyoVista to address this epidemic and enable low cost and effective screening of heart disease at an early stage using propriety technology and informatics.
“As someone whose family has been personally affected by heart disease, I am excited for the opportunity to work with Heart Test Labs in their efforts to bring the MyoVista to market” said David Lopez, Managing Director for OfferBoard. “Given the vast number of people affected by this condition, I am confident investors will relate and appreciate the possibility of the MyoVista becoming the standard of care in screening for heart disease in the near future.”
Positioned at the forefront of technology advancement in electrocardiography-based devices, the MyoVista uses sophisticated algorithms and easy to understand proprietary informatics to assist a physician to identify heart disease at an early stage. The MyoVista is expected to be in the hands of physicians and hospitals by the first quarter of 2016.
To view Heart Test Laboratories' offering page, please visit https://OfferBoard.com/htl
About Heart Test Laboratories, Inc.
Heart Test Laboratories, Inc. develops a medical device using patented technology that focus on the early detection of heart disease called MyoVista. By using standard 12-lead resting ECG protocols, the MyoVista provides an ECG test incorporating interpretive analysis, plus easy to understand proprietary informatics that assist a physician in identifying heart disease at an early stage. The MyoVista provides additional information to physicians in their decision process to refer patients to a cardiologist for further diagnostic testing and treatment.
Heart disease kills 7 million people worldwide each year, more than all cancers combined, and is the largest spend area in healthcare. The MyoVista helps to address the “diagnostic gap” in heart disease today, which is the identification of asymptomatic patients prior to an adverse cardiac event, such as a heart attack. For more information please visit https://www.hearttestlabs.com.
About OfferBoard Securities
OfferBoard Securities is a national investment bank and broker dealer with an equity-funding platform, headquartered in Princeton, New Jersey. OfferBoard Securities advises private companies raising $2 to $200 million in capital, including mergers, acquisitions, and divestitures. The OfferBoard team is backed by more than 75 years of experience from companies including Second Market, Goldman Sachs, JP Morgan Chase Bank and the Asian Development Bank, among others. OfferBoard Securities is member FINRA/SIPC.
To learn more about Heart Test Laboratories, Inc. on OfferBoard, please contact David Lopez, Managing Director, at (310) 402-6992.